Biological target (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Biological target" in English language version.

refsWebsite

Global rank English rank

16nih.gov

4^th place

14doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

4harvard.edu

18^th place

17^th place

1inkling.com

low place

doi.org

Raffa RB, Porreca F (1989). "Thermodynamic analysis of the drug-receptor interaction". Life Sciences. 44 (4): 245–58. doi:10.1016/0024-3205(89)90182-3. PMID 2536880.
Moy VT, Florin EL, Gaub HE (October 1994). "Intermolecular forces and energies between ligands and receptors". Science. 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). "Drugs and their molecular targets: an updated overview". Fundamental & Clinical Pharmacology. 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Lundstrom K (2009). "An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs". G Protein-Coupled Receptors in Drug Discovery. Methods in Molecular Biology. Vol. 552. pp. 51–66. doi:10.1007/978-1-60327-317-6_4. ISBN 978-1-60327-316-9. PMC 7122359. PMID 19513641.
Dixon SJ, Stockwell BR (December 2009). "Identifying druggable disease-modifying gene products". Current Opinion in Chemical Biology. 13 (5–6): 549–55. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). "Opportunities and challenges in phenotypic drug discovery: an industry perspective". Nature Reviews. Drug Discovery. 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
Lee H, Lee JW (2016). "Target identification for biologically active small molecules using chemical biology approaches". Archives of Pharmacal Research. 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Lomenick B, Olsen RW, Huang J (January 2011). "Identification of direct protein targets of small molecules". ACS Chemical Biology. 6 (1): 34–46. doi:10.1021/cb100294v. PMC 3031183. PMID 21077692.
Jung HJ, Kwon HJ (2015). "Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery". Archives of Pharmacal Research. 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). "Evolutionary conservation of human drug targets in organisms used for environmental risk assessments". Environmental Science & Technology. 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Larsson DG, Adolfsson-Erici M, Parkkonen J, Pettersson M, Berg AM, Olsson PE, Förlin L (April 1999). "Ethinyloestradiol — an undesired fish contraceptive?". Aquatic Toxicology. 45 (2–3): 91–97. doi:10.1016/S0166-445X(98)00112-X.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). "Repeating history: pharmaceuticals in the environment". Environmental Science & Technology. 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). "Risks to aquatic organisms posed by human pharmaceutical use". The Science of the Total Environment. 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

harvard.edu

ui.adsabs.harvard.edu

Moy VT, Florin EL, Gaub HE (October 1994). "Intermolecular forces and energies between ligands and receptors". Science. 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). "Evolutionary conservation of human drug targets in organisms used for environmental risk assessments". Environmental Science & Technology. 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). "Repeating history: pharmaceuticals in the environment". Environmental Science & Technology. 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). "Risks to aquatic organisms posed by human pharmaceutical use". The Science of the Total Environment. 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

inkling.com

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). "Chapter 2: How drugs act: general principles". Rang and Dale's Pharmacology. Edinburgh; New York: Elsevier/Churchill Livingstone. pp. 6–19. ISBN 978-0-7020-3471-8.

nih.gov

pubmed.ncbi.nlm.nih.gov

Raffa RB, Porreca F (1989). "Thermodynamic analysis of the drug-receptor interaction". Life Sciences. 44 (4): 245–58. doi:10.1016/0024-3205(89)90182-3. PMID 2536880.
Moy VT, Florin EL, Gaub HE (October 1994). "Intermolecular forces and energies between ligands and receptors". Science. 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). "Drugs and their molecular targets: an updated overview". Fundamental & Clinical Pharmacology. 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Lundstrom K (2009). "An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs". G Protein-Coupled Receptors in Drug Discovery. Methods in Molecular Biology. Vol. 552. pp. 51–66. doi:10.1007/978-1-60327-317-6_4. ISBN 978-1-60327-316-9. PMC 7122359. PMID 19513641.
Dixon SJ, Stockwell BR (December 2009). "Identifying druggable disease-modifying gene products". Current Opinion in Chemical Biology. 13 (5–6): 549–55. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). "Opportunities and challenges in phenotypic drug discovery: an industry perspective". Nature Reviews. Drug Discovery. 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
Lee H, Lee JW (2016). "Target identification for biologically active small molecules using chemical biology approaches". Archives of Pharmacal Research. 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Lomenick B, Olsen RW, Huang J (January 2011). "Identification of direct protein targets of small molecules". ACS Chemical Biology. 6 (1): 34–46. doi:10.1021/cb100294v. PMC 3031183. PMID 21077692.
Jung HJ, Kwon HJ (2015). "Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery". Archives of Pharmacal Research. 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). "Evolutionary conservation of human drug targets in organisms used for environmental risk assessments". Environmental Science & Technology. 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). "Repeating history: pharmaceuticals in the environment". Environmental Science & Technology. 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). "Risks to aquatic organisms posed by human pharmaceutical use". The Science of the Total Environment. 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

ncbi.nlm.nih.gov

Lundstrom K (2009). "An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs". G Protein-Coupled Receptors in Drug Discovery. Methods in Molecular Biology. Vol. 552. pp. 51–66. doi:10.1007/978-1-60327-317-6_4. ISBN 978-1-60327-316-9. PMC 7122359. PMID 19513641.
Dixon SJ, Stockwell BR (December 2009). "Identifying druggable disease-modifying gene products". Current Opinion in Chemical Biology. 13 (5–6): 549–55. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.
Lomenick B, Olsen RW, Huang J (January 2011). "Identification of direct protein targets of small molecules". ACS Chemical Biology. 6 (1): 34–46. doi:10.1021/cb100294v. PMC 3031183. PMID 21077692.

semanticscholar.org

api.semanticscholar.org

Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). "Drugs and their molecular targets: an updated overview". Fundamental & Clinical Pharmacology. 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). "Opportunities and challenges in phenotypic drug discovery: an industry perspective". Nature Reviews. Drug Discovery. 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
Lee H, Lee JW (2016). "Target identification for biologically active small molecules using chemical biology approaches". Archives of Pharmacal Research. 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Jung HJ, Kwon HJ (2015). "Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery". Archives of Pharmacal Research. 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.